Over the past few years, we’ve seen a clear pattern: multinational corporations scaling back, switching to third-party models, downsizing, or exiting last frontier markets. Across Africa, Latin America, and parts of Asia, this shift has occurred with notable consistency.
The official reasons sound familiar: FX volatility, political uncertainty, regulatory complexity, low margins, fragmented demand. And strategically, the narrative makes sense: consolidate resources where returns are higher.
But the strategic pivot towards “de-risked” models and reduced complexity has had predictable consequences. Access to high-quality medicines and innovative therapies has been affected, raising concerns among patients, healthcare professionals, and public authorities. In many cases, these moves appear misaligned with corporate mission statements and sustainability commitments, impacting brand perception and stakeholder trust.
BACKGROUND
Supported healthcare organizations in expanding their operations into the rapidly growing emerging, and frontier markets by offering strategies that address market challenges, with sustainable impact and business growth. Engage with South-South partnerships for the market expansion, based on an extensive network of strategic partners, including governmental entities, non-governmental organizations, health institutions, and industry associations.
